Lek's Half-Yearly Sales up 23 Percent, Further Growth Expects on U.S. Market
Ljubljana, 5 August - Slovenia's second-largest pharmaceutical company, the Ljubljana-based Lek, managed to beat its forecasts for the first half of 2002, selling a total of SIT 46bn (EUR 202m) worth of products. The six-month turnover represent a 23-percent increase over the same period last year, Lek CEO Metod Dragonja, who expects similar growth in the second half of the year, especially on the back of strong sales in the U.S., told the press on Monday.
The rest of this news item is available to subscribers.
The news item consists of 1.387 characters (without spaces) or 275 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.